Kauppila M, Koskinen P, Pulkki K, Sonninen P, Remes K, Irjala K, Viikari J
Department of Medicine,Turku University Central Hospital,Turku, Finland.
Clin Lab Haematol. 2000 Feb;22(1):15-20. doi: 10.1046/j.1365-2257.2000.00269.x.
Interferon-alpha (IFN-alpha) is used in the treatment of many haematological diseases and it is known that IFN-alpha may affect bone turnover. The effect of IFN-alpha on bone metabolism was studied in 10 haematological patients. The mean duration of the treatment was 4 (range: 2.8-7.2) months. Besides the usual markers of bone metabolism, levels of the cross-linked C-terminal telopeptide of type I collagen (ICTP), the N-terminal propeptide of type I procollagen (PINP) and the bone-specific alkaline phosphatase were measured. The bone mineral density was measured by computed tomography. During IFN-alpha treatment, serum ICTP decreased from a mean of 5.4 (range: 1.8-12.4) to 3.6 (range: 1.4-8.8) microg/l (P = 0.017). All other variables reflecting bone metabolism remained unaltered during IFN-alpha treatment. The bone mineral density remained unchanged. It was concluded that the observed decrease in ICTP may be an indicator of a beneficial therapeutic effect of IFN-alpha on bone turnover, resulting in decreased bone resorption. However, it is possible that elevated pretreatment ICTP values reflected disease of the bone marrow.
α干扰素（IFN-α）用于治疗多种血液系统疾病，且已知IFN-α可能影响骨转换。在10例血液系统疾病患者中研究了IFN-α对骨代谢的影响。治疗的平均持续时间为4个月（范围：2.8 - 7.2个月）。除了常用的骨代谢标志物外，还测量了I型胶原交联C末端肽（ICTP）、I型前胶原N末端前肽（PINP）和骨特异性碱性磷酸酶的水平。通过计算机断层扫描测量骨密度。在IFN-α治疗期间，血清ICTP从平均5.4μg/l（范围：1.8 - 12.4μg/l）降至3.6μg/l（范围：1.4 - 8.8μg/l）（P = 0.017）。在IFN-α治疗期间，所有其他反映骨代谢的变量均保持不变。骨密度也保持不变。得出的结论是，观察到的ICTP降低可能是IFN-α对骨转换产生有益治疗效果的一个指标，导致骨吸收减少。然而，有可能治疗前ICTP值升高反映了骨髓疾病。
